Navigation Links
Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
Date:4/12/2011

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA.  The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011.  Jim Scopa from MPM will join the Conatus Board of Directors.

Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.

"We've watched the progress at Conatus and believe that CTS-1027 could make a significant difference in the treatment of HCV infection.  MPM also expects to provide other resources, both strategic and clinical, to assist the management team in the execution of its business plan", said Jim Scopa, Managing Director of MPM Capital.

"The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010," said Steven J. Mento, Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
2. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
3. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
10. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
11. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... 19, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... on Friday, July 28, 2017, beginning at 7:30 a.m. (CDT) ... Dial-in information: To participate in the conference call, dial (877) ... call at least 10 minutes prior to the start to ... Webcast: A simultaneous webcast ...
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/12/2017)... June 12, 2017 Kineta, Inc., a biotechnology company ... Kineta Vice President of R&D and Head of Virology ... Pandemic Preparedness for the Northwest and Beyond meeting sponsored ... June 14, 2017 from 8:30-10:30 AM PDT at the Agora ... Dr. Bedard will be joined by other leaders ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a ... in select Florida and Texas doctors' offices and clinics. This breakthrough testing is ... genetic testing recognizes the role genes play in determining an individual's tolerance of ...
(Date:6/24/2017)... ... , ... Doorknobs are for convenience, deadbolts are for security. , There are ... having an alarm system installed. But unless there is a working deadbolt lock that ... TX Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders ...
(Date:6/23/2017)... MA (PRWEB) , ... June 23, 2017 , ... ... Care Reconciliation Act (BCRA), their proposed healthcare bill to repeal and replace the ... May, the Senate bill would make significant cuts to Medicaid, a public health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran advocate ... JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight of ... dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting photos ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat ... new videos highlight the importance of correctly using a meat thermometer. The videos ... done extensive research on consumer food safety habits. Dr. Bruhn explains the variety ...
Breaking Medicine News(10 mins):